190 related articles for article (PubMed ID: 32917576)
1. Bortezomib, Lenalidomide, and Dexamethasone in Elderly Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.
Chahine C; Roos-Weil D; Saada V; de Botton S; Micol JB; Barete S; Marzac C; Ghez D
Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):e986-e989. PubMed ID: 32917576
[No Abstract] [Full Text] [Related]
2. Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
Jung KS; Kim K; Kim HJ; Kim SH; Lee JO; Kim JS; Lee JJ; Eom HS; Min CK; Shin HJ
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e97-e104. PubMed ID: 31831372
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.
Montefusco V; Corso A; Galli M; Ardoino I; Pezzatti S; Carniti C; Patriarca F; Gherlinzoni F; Zambello R; Sammassimo S; Marcatti M; Nozza A; Crippa C; Cafro AM; Baldini L; Corradini P
Br J Haematol; 2020 Mar; 188(6):907-917. PubMed ID: 31898319
[TBL] [Abstract][Full Text] [Related]
4. The lenalidomide/bortezomib/dexamethasone regimen for the treatment of blastic plasmacytoid dendritic cell neoplasm.
Marmouset V; Joris M; Merlusca L; Beaumont M; Charbonnier A; Marolleau JP; Gruson B
Hematol Oncol; 2019 Oct; 37(4):487-489. PubMed ID: 31465531
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm.
Philippe L; Ceroi A; Bôle-Richard E; Jenvrin A; Biichle S; Perrin S; Limat S; Bonnefoy F; Deconinck E; Saas P; Garnache-Ottou F; Angelot-Delettre F
Haematologica; 2017 Nov; 102(11):1861-1868. PubMed ID: 28798071
[TBL] [Abstract][Full Text] [Related]
6. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
7. Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm.
Agha ME; Monaghan SA; Swerdlow SH
N Engl J Med; 2018 Oct; 379(15):1479-1481. PubMed ID: 30304659
[No Abstract] [Full Text] [Related]
8. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).
Durie BGM; Hoering A; Sexton R; Abidi MH; Epstein J; Rajkumar SV; Dispenzieri A; Kahanic SP; Thakuri MC; Reu FJ; Reynolds CM; Orlowski RZ; Barlogie B
Blood Cancer J; 2020 May; 10(5):53. PubMed ID: 32393732
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
Kaufman JL; Mina R; Shah JJ; Laubach JP; Nooka AK; Lewis C; Gleason C; Sharp C; Harvey RD; Heffner LT; Richardson P; Lonial S; Orlowski RZ
Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):797-803. PubMed ID: 32819881
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib.
Mian M; Pescosta N; Badiali S; Cappelletto PC; Marcheselli L; Luminari S; Patriarca F; Zambello R; Pascarella A; Tagariello G; Marabese A; Mondello P; Billio A; Cortelazzo S
Br J Haematol; 2019 Jun; 185(5):944-947. PubMed ID: 30478966
[No Abstract] [Full Text] [Related]
11. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma.
Laubach JP; Tuchman SA; Rosenblatt JM; Mitsiades CS; Colson K; Masone K; Warren D; Redd RA; Grayson D; Richardson PG
Blood Cancer J; 2021 Feb; 11(2):20. PubMed ID: 33563894
[TBL] [Abstract][Full Text] [Related]
13. Combination Lenalidomide/Bortezomib Treatment Synergistically Induces Calpain-Dependent Ikaros Cleavage and Apoptosis in Myeloma Cells.
Ganesan S; Palani HK; Balasundaram N; David S; Devasia AJ; George B; Mathews V
Mol Cancer Res; 2020 Apr; 18(4):529-536. PubMed ID: 31915234
[TBL] [Abstract][Full Text] [Related]
14. Elotuzumab in the treatment of relapsed and refractory multiple myeloma.
Grosicki S; Bednarczyk M; Barchnicka A; Grosicka O
Future Oncol; 2021 May; 17(13):1581-1591. PubMed ID: 33478270
[TBL] [Abstract][Full Text] [Related]
15. Selinexor, Bortezomib, and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series.
Magen H; Geva M; Volchik Y; Avigdor A; Nagler A
Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):e947-e955. PubMed ID: 32868229
[No Abstract] [Full Text] [Related]
16. [Successful disease control of plasma cell leukemia by the treatment comprising proteasome inhibitors, followed by daratumumab, lenalidomide, and dexamethasone therapy].
Nakamura A; Yamaguchi T; Ito R; Kawakami K
Rinsho Ketsueki; 2020; 61(11):1600-1604. PubMed ID: 33298653
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide with dexamethasone to multiple myeloma patients relapsing from bortezomib-based induction therapies: A prospective, observational study.
Tan TD; Hong YC; Li SS; Yu JT; Sung YC; Wang PN; Teng CJ
Chin J Physiol; 2020; 63(5):211-217. PubMed ID: 33109787
[TBL] [Abstract][Full Text] [Related]
18. Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment-resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma.
Iqbal SM; Stecklein K; Sarow J; Krabak M; Hillengass J; McCarthy P
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):e33-e36. PubMed ID: 30337238
[No Abstract] [Full Text] [Related]
19. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
Chari A; Parikh K; Ni Q; Abouzaid S
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
[TBL] [Abstract][Full Text] [Related]
20. Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma.
Mancuso K; Tacchetti P; Pantani L; Rocchi S; Rizzello I; Caratozzolo I; De Cicco G; Fusco A; Testoni N; Terragna C; Marzocchi G; Martello M; Borsi E; Dozza L; Cavo M; Zamagni E
Bone Marrow Transplant; 2020 Sep; 55(9):1865-1867. PubMed ID: 32103147
[No Abstract] [Full Text] [Related]
[Next] [New Search]
